Non-Opioid Pain Treatments Likely Not Eligible For Accelerated Approval, US FDA Says
Other expedited pathways like fast track, priority review or breakthrough could be appropriate, according to new draft guidance.
Other expedited pathways like fast track, priority review or breakthrough could be appropriate, according to new draft guidance.